Table 3.
MALE |
FEMALE |
|||||||
---|---|---|---|---|---|---|---|---|
Vehicle sca |
Insulin sc |
Vehicle sc |
Insulin sc |
|||||
Vehicle icv b | Vehicle icv | MPPc icv | PHTPPd icv | Vehicle icv | Vehicle icv | MPP icv | PHTPP icv | |
V/V n=6 | V/INSe n=6 | MPP/INS n=6 | PHTPP/INS n=6 | V/V n=6 | V/INS n=6 | MPP/INS n=6 | PHTPP/INS n=6 | |
Alpha1-AR | ↓f vs V/V | ↑ vs V/INS Ng | N.C.h vs V/INS | N.C. vs V/V | ↑ vs V/INS | N.C. vs V/INS | ||
Alpha2-AR | N.C. vs V/V | N.C. vs V/INS | N.C. vs V/INS | ↓ vs V/V | ↑ vs V/INS N | ↑ vs V/INS N | ||
Beta1-AR | ↓ vs V/V | ↑ vs V/INS N | N.C. vs V/INS | ↓ vs V/V | N.C. vs V/INS | N.C. vs V/INS | ||
ER-alpha | ↓ vs V/V | ↑ vs V/INS N | N.C. V/INS | ↓ vs. Male V/V | ↑ vs V/V | ↓ vs V/INS N | ↓ vs V/INS N | |
ER-beta | ↑ vs V/V | ↓ vs V/INS N | ↓ vs V/INS N | ↑ vs V/V | ↓ vs V/INS N | ↓ vs V/INS N | ||
GPERi | N.C. vs V/V | N.C. vs V/INS | ↓ vs V/INS | N.C. vs V/V | ↑ vs V/INS | N.C. vs V/INS | ||
MCT2j | N.C. vs V/V | N.C. vs V/INS | ↑ vs V/INS | ↑ vs V/V | N.C. vs V/INS | ↑ vs V/INS | ||
GLSk | ↓ vs V/V | ↑ vs V/INS N | N.C. vs V/INS N | ↓ vs V/V | N.C. vs V/INS | ↑ vs V/INS N | ||
ME-1l | ↑ vs V/V | N.C. vs V/INS | ↓ vs V/INS N | N.C. V/INS | N.C. vs V/INS | ↑ vs V/INS |
subcutaneous
intracerebroventricular
1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride
4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol
insulin
arrows indicate a significant difference of at least p<0.05
N normalized relative to V/V
no change
G protein-coupled estrogen receptor-1
monocarboxylate transporter-2
glutaminase
malic enzyme-1